Profile data is unavailable for this security.
About the company
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
- Revenue in SEK (TTM)382.22m
- Net income in SEK-51.49m
- Incorporated2010
- Employees101.00
- LocationBonesupport Holding ABScheelevagen 19LUND 223 70SwedenSWE
- Phone+46 462865370
- Fax+46 462865371
- Websitehttps://www.bonesupport.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ultimovacs ASA | 0.00 | -161.02m | 3.95bn | 24.00 | -- | 9.58 | -- | -- | -4.82 | -4.82 | 0.00 | 12.30 | 0.00 | -- | -- | 0.00 | -30.14 | -25.92 | -32.89 | -27.77 | -- | -- | -- | -- | -- | -- | 0.0118 | -- | -- | -- | -1.86 | -- | 56.16 | -- |
| MedCap AB (publ) | 1.11bn | 117.50m | 4.66bn | 368.00 | 39.70 | 5.45 | 22.64 | 4.20 | 7.94 | 7.94 | 75.04 | 57.83 | 0.8552 | 3.71 | 7.23 | 3,019,565.00 | 9.08 | 7.70 | 11.51 | 10.71 | 47.81 | 45.26 | 10.62 | 8.46 | 1.92 | 8.99 | 0.2836 | 0.00 | 21.28 | -- | 21.87 | -- | -- | -- |
| Calliditas Therapeutics AB | 944.50m | -392.75m | 5.66bn | 181.00 | -- | 8.65 | -- | 5.99 | -7.35 | -7.35 | 17.71 | 10.98 | 0.6029 | 3.55 | 16.30 | 9,259,775.00 | -25.07 | -27.85 | -29.58 | -30.95 | 97.50 | -- | -41.58 | -125.04 | 3.89 | -31.87 | 0.5589 | -- | 250.07 | -- | 17.59 | -- | -- | -- |
| Swedencare AB (publ) | 1.98bn | 86.32m | 7.41bn | 490.00 | 85.54 | 0.9972 | 20.45 | 3.75 | 0.5461 | 0.5461 | 12.49 | 46.84 | 0.2065 | 2.09 | 9.23 | 4,069,475.00 | 0.9011 | 2.37 | 0.9372 | 2.46 | 55.52 | 56.05 | 4.36 | 7.67 | 2.29 | 2.46 | 0.2028 | 36.63 | 137.23 | 84.63 | 72.92 | 40.89 | 137.91 | -- |
| Bonesupport Holding AB | 382.22m | -51.49m | 7.48bn | 101.00 | -- | 27.96 | -- | 19.57 | -0.7981 | -0.7981 | 5.92 | 4.11 | 1.08 | 0.6662 | 6.51 | 4,246,867.00 | -14.53 | -32.63 | -18.67 | -40.52 | 90.53 | 88.89 | -13.47 | -60.80 | 3.09 | -404.37 | 0.0568 | -- | 54.46 | 20.52 | 20.30 | -- | -6.59 | -- |
| Nykode Therapeutics ASA | 103.35m | -498.55m | 8.14bn | 158.00 | -- | 5.09 | -- | 78.79 | -1.74 | -1.74 | 0.3613 | 5.56 | 0.0417 | -- | 7.63 | 684,474.80 | -20.12 | 11.35 | -23.39 | 12.68 | -- | -- | -482.43 | 29.70 | -- | -- | 0.0358 | -- | -78.89 | 161.32 | -354.04 | -- | 212.66 | -- |
| BioGaia AB | 1.19bn | 413.42m | 9.76bn | 211.00 | 24.50 | 4.85 | 22.29 | 8.23 | 4.09 | 4.09 | 11.74 | 20.67 | 0.5208 | -- | -- | 5,593,977.00 | 18.16 | 17.02 | 19.62 | 18.91 | 72.71 | 73.60 | 34.86 | 27.77 | -- | -- | 0.00 | 74.20 | 40.61 | 12.41 | 90.44 | 15.66 | -7.62 | 10.01 |
Data as of May 29 2023. Currency figures normalised to Bonesupport Holding AB's reporting currency: Swedish Krona SEK
37.42%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Swedbank Robur Fonder ABas of 28 Apr 2023 | 6.09m | 9.37% |
| Fj�rde AP-fondenas of 28 Nov 2022 | 3.22m | 4.95% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2023 | 2.90m | 4.45% |
| Tredje AP-fondenas of 28 Nov 2022 | 2.82m | 4.33% |
| Financi�re de l'�chiquier SAas of 30 Jun 2022 | 2.52m | 3.87% |
| Lancelot Asset Management ABas of 28 Nov 2022 | 2.40m | 3.69% |
| Norges Bank Investment Managementas of 28 Nov 2022 | 1.64m | 2.53% |
| Handelsbanken Fonder ABas of 30 Apr 2023 | 1.21m | 1.85% |
| Carnegie Fonder ABas of 28 Apr 2023 | 833.55k | 1.28% |
| AXA Investment Managers (Paris) SAas of 30 Sep 2022 | 720.00k | 1.11% |
More ▼
Data from 30 Jun 2022 - 28 Apr 2023Source: FactSet Research Systems Inc.
